Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
BioNTech's mRNA immunotherapy BNT113 (tenumomeran/raplemomeran) combined with pembrolizumab failed to significantly improve progression-free survival vs. pembrolizumab alone in HPV16-positive head and neck cancer. The phase 3 AHEAD-MERIT trial missed its PFS primary endpoint, but the trial continues to evaluate overall survival — which could still deliver a positive result.
BioNTech's investigational mRNA cancer immunotherapy, tenumomeran/raplemomeran (BNT113), combined with pembrolizumab (Keytruda) did not significantly improve progression-free survival (PFS) compared to pembrolizumab alone in patients with unresectable recurrent or metastatic, HPV16-positive, PD-L1–expressing head and neck squamous cell carcinoma (HNSCC). The result comes from the phase 3 portion of the AHEAD-MERIT trial and marks a setback for the combination approach.
Despite missing the PFS endpoint, BioNTech's independent data monitoring committee has recommended continuing the trial to assess overall survival (OS) — the second co-primary endpoint. Under the trial's prespecified statistical design, a significant OS improvement could still establish a positive outcome. BioNTech's CMO noted that immune-mediated anti-tumor effects can deepen over time, making the OS analysis critical to fully evaluating the therapy's potential.
Key Takeaways:
Why it matters: HPV16-positive HNSCC represents a distinct and growing patient population with limited first-line options. While the PFS miss is a notable setback, the OS readout will be the true test of whether mRNA-based cancer immunotherapy can deliver durable benefit in this setting.
